Information About Canadian Patient Groups' Conflicts of Interest and Industry Funding-Incomplete, Inconsistent, and Unreliable: A Cross-Sectional Study

被引:0
作者
Lexchin, Joel [1 ,2 ]
机构
[1] York Univ, Sch Hlth Policy & Management, Toronto, ON, Canada
[2] Univ Toronto, Fac Med, Toronto, ON, Canada
基金
加拿大健康研究院;
关键词
PHARMACEUTICAL-INDUSTRY; ORGANIZATIONS;
D O I
10.1177/27551938251325801
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Patient groups play an important role in health care. At the same time, the majority of Canadian groups receive payments from pharmaceutical companies, which calls into question whether they speak for the best interests of their membership or the companies that fund them. Canada lacks any mandatory reporting by either patient groups or pharmaceutical companies regarding payments between groups and companies. There are three potential sources of information on the topic of payments: (a) declarations made by groups when they file submissions to the Canadian Agency for Drugs and Technologies in Health, an organization created and funded by Canada's federal, provincial and territorial governments, about whether the agency should recommend public funding for the new drug; (b) patient groups' websites; and (c) voluntary disclosures by pharmaceutical companies on their websites. This study investigates the data available in all three sources and finds that they are incomplete and inconsistent, making any conclusions about patient groups' conflicts of interest and funding unreliable. Although increased transparency is no guarantee of independence, it is an important and necessary first step. However, relying on voluntary disclosure is not sufficient. Legislation, such as the bill passed in the province of Ontario but never implemented, mandating disclosure by companies of payments that they have made is necessary.
引用
收藏
页数:16
相关论文
共 34 条
[1]  
[Anonymous], Structure and principles
[2]  
[Anonymous], Reimburse review reports
[3]  
bankofcanada, Annual exchange rates
[4]  
Batt S., 2017, HLTH ADVOCACY INC PH
[5]   Risky business? Pharmaceutical industry sponsorship of health consumer groups [J].
Bero, Lisa A. ;
Parker, Lisa .
AUSTRALIAN PRESCRIBER, 2021, 44 (03) :74-76
[6]  
Burton Bob, 2005, BMJ, V331, P1359, DOI 10.1136/bmj.331.7529.1359-b
[7]  
Canadas Drug Agency, Procedures for reimbursement reviews
[8]  
Canadian Agency for Drugs and Technologies in Health (CADTH), 2018, Clinical review report: cysteamine delayed-release capsules (Procysbi)
[9]  
Claypool R., 2016, Patients' groups and big pharma
[10]   Patient Organizations' Funding from Pharmaceutical Companies: Is Disclosure Clear, Complete and Accessible to the Public? An Italian Survey [J].
Colombo, Cinzia ;
Mosconi, Paola ;
Villani, Walter ;
Garattini, Silvio .
PLOS ONE, 2012, 7 (05)